PT3442557T - Uma formulação de fármaco para utilização no controlo eficaz de dor aguda e/ou crónica - Google Patents

Uma formulação de fármaco para utilização no controlo eficaz de dor aguda e/ou crónica

Info

Publication number
PT3442557T
PT3442557T PT177827565T PT17782756T PT3442557T PT 3442557 T PT3442557 T PT 3442557T PT 177827565 T PT177827565 T PT 177827565T PT 17782756 T PT17782756 T PT 17782756T PT 3442557 T PT3442557 T PT 3442557T
Authority
PT
Portugal
Prior art keywords
acute
administration
drug
chronic pain
effective control
Prior art date
Application number
PT177827565T
Other languages
English (en)
Original Assignee
Pvp Labs Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10201602973WA external-priority patent/SG10201602973WA/en
Priority claimed from RU2016133329A external-priority patent/RU2622980C3/ru
Application filed by Pvp Labs Pte Ltd filed Critical Pvp Labs Pte Ltd
Publication of PT3442557T publication Critical patent/PT3442557T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT177827565T 2016-04-14 2017-04-13 Uma formulação de fármaco para utilização no controlo eficaz de dor aguda e/ou crónica PT3442557T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201602973WA SG10201602973WA (en) 2016-04-14 2016-04-14 Method of development of an analgesic peptide preparation, for the treatment of acute and chronic pain
RU2016133329A RU2622980C3 (ru) 2016-08-12 Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения

Publications (1)

Publication Number Publication Date
PT3442557T true PT3442557T (pt) 2022-11-23

Family

ID=60042549

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177827565T PT3442557T (pt) 2016-04-14 2017-04-13 Uma formulação de fármaco para utilização no controlo eficaz de dor aguda e/ou crónica

Country Status (15)

Country Link
US (1) US10357533B2 (pt)
EP (1) EP3442557B1 (pt)
CN (1) CN108697758B (pt)
CA (1) CA3056222C (pt)
DK (1) DK3442557T3 (pt)
ES (1) ES2930757T3 (pt)
FI (1) FI3442557T3 (pt)
HR (1) HRP20221395T1 (pt)
HU (1) HUE060669T2 (pt)
LT (1) LT3442557T (pt)
PL (1) PL3442557T3 (pt)
PT (1) PT3442557T (pt)
RS (1) RS63779B1 (pt)
SI (1) SI3442557T1 (pt)
WO (1) WO2017180064A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019219019A1 (zh) * 2018-05-16 2019-11-21 江苏恒瑞医药股份有限公司 一种kor受体激动剂药物组合物
US20240239840A1 (en) * 2023-01-18 2024-07-18 Pvp Labs Pte.Ltd. method for the treatment of pain and a medicinal product for administration during pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58213743A (ja) * 1982-06-07 1983-12-12 Dai Ichi Seiyaku Co Ltd テトラペプチド誘導体
JPS6054400B2 (ja) 1982-12-27 1985-11-29 黒沢通信工業株式会社 めつき装置
JPS6054400A (ja) * 1983-09-01 1985-03-28 Grelan Pharmaceut Co Ltd テトラペプチド
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
RU2538727C1 (ru) 2013-11-15 2015-01-10 Закрытое акционерное общество "Институт экспериментальной фармакологии" Анальгетическое средство пептидной структуры на основе тридекапептида, содержащего d-октааргининовый вектор

Also Published As

Publication number Publication date
EP3442557A4 (en) 2019-12-25
LT3442557T (lt) 2022-12-12
US20180221432A1 (en) 2018-08-09
WO2017180064A1 (en) 2017-10-19
CN108697758A (zh) 2018-10-23
CA3056222A1 (en) 2017-10-19
PL3442557T3 (pl) 2023-01-09
ES2930757T3 (es) 2022-12-21
EP3442557A1 (en) 2019-02-20
CN108697758B (zh) 2022-12-02
EP3442557B1 (en) 2022-10-05
CA3056222C (en) 2020-09-29
HRP20221395T1 (hr) 2023-01-06
RS63779B1 (sr) 2022-12-30
DK3442557T3 (da) 2022-11-28
US10357533B2 (en) 2019-07-23
HUE060669T2 (hu) 2023-04-28
FI3442557T3 (fi) 2022-12-15
SI3442557T1 (sl) 2023-01-31

Similar Documents

Publication Publication Date Title
IL254746A0 (en) A system and method for controlling the administration of a drug to a patient
IL260290A (en) Systems and methods for long-term percutaneous administration
ZA201901504B (en) System and method for controlled medical therapy
IL268385B (en) Drug delivery devices and drug delivery methods
ES3063958T3 (en) System and method for improving the drug therapy management
SI4335517T1 (sl) Dajanje in odmerek diaminofenotiazinov
EP3253451A4 (en) Diagnosis and treatment of chronic pain
IL267622A (en) Method for modifying the therapeutic effects of drugs
SG11201703913YA (en) Iontophoresis Device For Drug Delivery And Method For Manufacturing The Same
SG11201913729TA (en) Catheter devices with blood control systems and related methods
IL282007A (en) Medicine to treat chronic cough
ZA201705561B (en) Kv1.3 inhibitors and their medical application
GB201711262D0 (en) Medicament dispensing system and dispensing method
IL270011B (en) Medicinal compounds and methods
ZA201802845B (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
PT3442557T (pt) Uma formulação de fármaco para utilização no controlo eficaz de dor aguda e/ou crónica
ZA201705676B (en) Kv1.3 inhibitors and their medical application
EP3383374A4 (en) SYSTEMS AND METHODS OF TRANSDERMAL DRUG DELIVERY
IL273500A (en) Treatment methods for acute or chronic pain
SG10201602973WA (en) Method of development of an analgesic peptide preparation, for the treatment of acute and chronic pain
GB201710382D0 (en) Administration and dosage of Diaminophenothiazines
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
HUE045679T2 (hu) Valentonint tartalmazó transzdermális terápiai rendszer, és annak alkalmazása gyógyszerként
AU2015900240A0 (en) Treatment of the inflammation and pain of acute and chronic gout